Synthetic lethality

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, February 11, 2021
Infectious causes of cancer, Branches of biology, Nasopharyngeal carcinoma, Pharynx, Cancer, Synthetic lethality

Upon completion of the Merger, the combined company will operate under the name Viracta Therapeutics, Inc. and intends to be listed on the Nasdaq Global Market under the ticker symbol "VIRX".

Key Points: 
  • Upon completion of the Merger, the combined company will operate under the name Viracta Therapeutics, Inc. and intends to be listed on the Nasdaq Global Market under the ticker symbol "VIRX".
  • Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
  • These documents can be accessed on Sunesis' Investor Relations page at https://ir.sunesis.com/shareholder-services/contact-ir by clicking on the link titled "SEC Filings."
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs

Retrieved on: 
Monday, February 8, 2021
Genetics, Synthetic lethality

IDEAYA is targeting a Q1 2021 First-Patient-In for the Phase 1 clinical trial of IDE397 in patients having solid tumors harboring MTAP deletion.

Key Points: 
  • IDEAYA is targeting a Q1 2021 First-Patient-In for the Phase 1 clinical trial of IDE397 in patients having solid tumors harboring MTAP deletion.
  • IDEAYA also announced thatMatthew Maurer, M.D., has joined the company as Vice President, Head of Clinical Oncology and Medical Affairs.
  • "Matt brings extensive clinical development and oncology experience in both the pharmaceutical industry and academia.
  • IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality which represents an emerging class of precision medicine targets.

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

Retrieved on: 
Monday, February 8, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Biology, Genetics, Synthetic lethality, Myc, Carcinogenesis, Stem cells, Biotechnology, Oncogenomics

Synthetic lethality is possible when the same genetic changes that enable carcinogenesis also make the cancer cell overly dependent on specific pathways and proteins.

Key Points: 
  • Synthetic lethality is possible when the same genetic changes that enable carcinogenesis also make the cancer cell overly dependent on specific pathways and proteins.
  • Attacking these dependencies with drugs can yield dramatic anti-cancer effects, while leaving normal cells healthy.
  • The synthetic lethal phenotype includes the induction of cell cycle arrest early in mitosis followed by accumulation of polyploid cells.
  • With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China.

Anticancer Bioscience Presenting at Biotech Showcase(TM) Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time

Retrieved on: 
Wednesday, January 13, 2021
Genetics, Synthetic lethality, Precision medicine

Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the first time, providing an on-demand company presentation.

Key Points: 
  • Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the first time, providing an on-demand company presentation.
  • Anticancer Bioscience is participating in Biotech Showcase Digital 2021.
  • The Company will showcase its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies.
  • Pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China.

IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

Retrieved on: 
Monday, January 11, 2021
Branches of biology, Life sciences, Biology, Biotechnology, Medical genetics, Systems biology, Genetics, Synthetic lethality, Molecular diagnostics, Precision medicine, Targeted therapy

"The IDE397 IND submission is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-in-class therapies.

Key Points: 
  • "The IDE397 IND submission is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-in-class therapies.
  • IDE397 was discovered through our efforts to develop a potential best-in-class MAT2A inhibitor, and we have achieved our target product profile," saidMichael Dillon, Ph.D., Chief Scientific Officer,IDEAYA Biosciences.
  • IDEAYABiosciences will present a program update on IDE397 and its broader synthetic lethality pipeline at the 39th Annual J.P. Morgan Healthcare Conference.
  • IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7

Branches of biology, Biology, DNA repair, Cellular processes, Molecular genetics, Mutation, Senescence, Homologous recombination, DNA mismatch repair, Genetic recombination, Synthetic lethality

Cellworks Omics Biology Model (CBM) analysis can identify genetic signatures associated with therapy response and non-response for AML patients with Monosomy 7 in advance of treatment, which in turn can inform therapy planning and improve patient outcomes.

Key Points: 
  • Cellworks Omics Biology Model (CBM) analysis can identify genetic signatures associated with therapy response and non-response for AML patients with Monosomy 7 in advance of treatment, which in turn can inform therapy planning and improve patient outcomes.
  • Cellworks CBM analysis identified other genomic alterations that determine chemotherapy response, which can enable a personalized approach to therapy.
  • Cellworks CBM analysis identified other genomic alterations that determine chemotherapy response, including DNA repair deficiency genes, mismatch repair (MMR), and homologous recombination repair (HRR) genes.
  • On the other hand, Cellworks CBM analysis identified genetic signatures associated with a 100% remission rate from AML induction therapy despite the presence of (-7).

IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform

Retrieved on: 
Thursday, October 22, 2020
Branches of biology, Biology, Articles, Genetics, Biotechnology, Synthetic lethality, Molecular biology, Emerging technologies, CRISPR, DDT

The IDEAYA partnership with the laboratory of William R. Sellers, M.D., Core Institute Member, Broad Institute, will utilize the CRISPR paralog screening platform developed at the Broad Institute to evaluate functionally redundant paralogous genesacross ovarian cancer subtypes and to generate novel Synthetic Lethality (SL) based target and biomarker discoveries.

Key Points: 
  • The IDEAYA partnership with the laboratory of William R. Sellers, M.D., Core Institute Member, Broad Institute, will utilize the CRISPR paralog screening platform developed at the Broad Institute to evaluate functionally redundant paralogous genesacross ovarian cancer subtypes and to generate novel Synthetic Lethality (SL) based target and biomarker discoveries.
  • In addition to its three GSK-partnered Synthetic Lethality programs in MAT2A, Pol Theta and Werner Helicase, IDEAYA has several wholly owned SL and DNA Damage Target (DDT) programs, including PARG and multiple additional SL / DDT preclinical programs.
  • "We are executing on our strategy to build the industry leading Synthetic Lethality focused biotechnology company, including through strategic partnerships.
  • The Broad and earlier announced GSK partnership advances our efforts to extend our research leadership in Synthetic Lethality and to build a diverse pipeline of potential first-in-class Synthetic Lethality programs," said Yujiro S. Hata, President and CEO, IDEAYA Biosciences.

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway

Retrieved on: 
Tuesday, August 25, 2020
Branches of biology, Biology, DNA repair, RAD52, Homologous recombination, PARP inhibitor, BRCA1, Synthetic lethality

RAD52 is a novel and rational oncology target, and weve been very impressed with the advances in the field made by Drexel researchers.

Key Points: 
  • RAD52 is a novel and rational oncology target, and weve been very impressed with the advances in the field made by Drexel researchers.
  • RAD52 is involved in several DDR pathways, and RAD52 inactivation is synthetically lethal in cancer cells with BRCA1/2 and other homologous recombination (HR) gene mutations.
  • Drexels RAD52-targeted inhibitors have evidenced potent in vitro and in vivo activity in BRCA1-deficient xenograft models, alone and in combination with PARP inhibitors.
  • Drexel University will also receive milestone payments and royalties based on successful development and commercialization of proprietary programs.

Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500

Retrieved on: 
Wednesday, July 29, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Pfizer, Synthetic lethality, Life sciences, Articles, Repare’s SNIPRx® Platform, Repare Therapeutics, Inc.

The primary outcome measure in the Phase 1 part of the study will be an assessment of safety and tolerability and determination of a dose for the Phase 2 portion of the trial.

Key Points: 
  • The primary outcome measure in the Phase 1 part of the study will be an assessment of safety and tolerability and determination of a dose for the Phase 2 portion of the trial.
  • The Phase 2 monotherapy portion of the trial is expected to further evaluate the efficacy of RP-3500 in biomarker-selected tumors.
  • Talazoparib is being provided by Pfizer to Repare for the purposes of the clinical trial.
  • Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team

Retrieved on: 
Tuesday, July 7, 2020
Branches of biology, Biology, DNA repair, RAD51, Cellular processes, Molecular genetics, Synthetic lethality, Genetic recombination, RAD54B

Additionally, the company announced the appointment of three senior executives, all with extensive pharmaceutical and biotechnology leadership experience.

Key Points: 
  • Additionally, the company announced the appointment of three senior executives, all with extensive pharmaceutical and biotechnology leadership experience.
  • Inhibiting RAD51-mediated homologous recombination in these cancer cells limits their ability to self-repair, leading to overwhelming DNA damage and ultimately, self-destruction a therapeutic effect known as synthetic lethality.
  • These findings support the broad potential for CYT-0851 to address the high unmet clinical need across various cancers and stages.
  • Cyteir Therapeutics, Cyteir, and associated logos are trademarks of Cyteir Therapeutics, Inc.